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A common founder for the 35delG GJB2 gene
mutation in connexin 26 hearing impairment
L Van Laer, P Coucke, R F Mueller, G Caethoven, K Flothmann, S D Prasad,
G P Chamberlin, M Houseman, G R Taylor, C M Van de Heyning, E Fransen, J Rowland,
R A Cucci, R J H Smith, G Van Camp
Abstract
Fifty to eighty percent of autosomal reces-
sive congenital severe to profound hearing
impairment result from mutations in a
single gene, GJB2, that encodes the pro-
tein connexin 26. One mutation of this
gene, the 35delG allele, is particularly
common in white populations. We report
evidence that the high frequency of this
allelic variant is the result of a founder
eVect rather than a mutational hot spot in
GJB2, which was the prevailing hypoth-
esis. Patients homozygous for the 35delG
mutation and normal hearing controls
originating from Belgium, the UK, and
the USA were genotyped for diVerent sin-
gle nucleotide polymorphisms (SNPs).
Four SNPs mapped in the immediate
vicinity ofGJB2, while two were positioned
up to 76 kb from it. Significant diVerences
between the genotypes of patients and
controls for the five SNPs closest to GJB2
were found, with nearly complete associ-
ation of one SNP allele with the 35delG
mutation. For the most remote SNP, we
could not detect any association. We
conclude that the 35delG mutation is
derived from a common, albeit ancient
founder.
(J Med Genet 2001;38:515–518)
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Congenital severe to profound hearing impair-
ment aVects 1 in 1000 neonates.1 In half of
these children, the hearing impairment is the
result of genetic factors,2 with autosomal
recessive inheritance representing approxi-
mately 80% of this total.1 Although 30
recessive genes have been localised (G Van
Camp, R J H Smith. Hereditary Hearing Loss
Homepage, http://dnalab-www.uia.ac.be/
dnalab/hhh, March 2001), a large proportion
of recessive severe to profound hearing
impairment has been linked to the DFNB1
locus.3 In 1997, Kelsell et al4 showed that
mutations in GJB2 lead to hearing impairment
at this locus. Mutations in the same gene also
are responsible for autosomal dominant hear-
ing impairment at the DFNA3 locus.5
GJB2 encodes connexin 26, a gap junction
protein that is assumed to be a component of
the potassium recycling pathway in the inner
ear. Loss or malfunction of these gap junctions,
as might be reflected by mutations in GJB2,
may disrupt potassium movement from the
hair cells through the supporting cell network
to the endolymph, leading to hearing impair-
ment. The resultant hearing loss involves all
frequencies, is of variable severity (from mild to
profound) even within sibships, rarely
progresses, and most frequently is symmetrical
in the two ears.6–8
To date, 48 recessive and seven dominant
disease causing GJB2 mutations have been
identified (R Rabionet, P Gasparini, X Estivill.
Connexins and Deafness Homepage, http//
www.iro.es/cx26deaf.html, March 2001). One
mutation, the deletion of one guanosine
residue from a stretch of six between nucle-
otide positions 30 and 35 (35delG), which
results in a frameshift and premature protein
truncation at codon 13, is the most common
deafness causing allelic variant of GJB2 in spo-
radic patients and autosomal recessive families
from Italy, Spain, Portugal, France, UK, Israel,
Lebanon, Tunisia, Algeria, New Zealand, and
in white American families of northern and
southern European origin.9–13
Carrier frequencies of the 35delG mutation
have been determined in several countries
(table 1), and in some populations this
mutation is more frequent than the ÄF508
cystic fibrosis mutation. However, in non-white
populations, the 35delG mutation is either not
found or is very rare, with other “common”
mutations prevailing, like the 235delC in the
Japanese and Koreans,14–16 the 167delT in the
Ashkenazi Jewish,17 18 and the R143W muta-
tion in an African village.19 Most investigators
have assumed that the high frequency of the
35delG mutation reflects the presence of a
mutational hot spot within GJB2,9 11 17 20 21 but
others have suggested a founder eVect.13 To
resolve the issue, we performed genotyping in
the immediate vicinity of the GJB2 gene. From
these data, we present evidence that the high
frequency of the 35delG GJB2 allelic variant in
the white population is the result of a founder
eVect rather than a mutational hot spot.
Subjects and methods
SUBJECTS
In this study, the following subjects were geno-
typed: 35 Belgian, 30 British, and 49 American
white patients with non-syndromic hearing
impairment who were homozygous for the
35delG mutation, and 70 Belgian, 30 British,
and 50 American white random normal
hearing controls. The American control sam-
ples were screened and selected for the absence
of the 35delG mutation. In the Belgian and
British control samples, no 35delG genotyping
was performed.
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SNP IDENTIFICATION
To identify SNPs (single nucleotide polymor-
phisms) in regions adjacent to the GJB2 gene,
the 3'UTR (untranslated region, Genbank
accession number M86849), and the URR
(upstream regulatory region, Genbank acces-
sion number AF091526) were sequenced in six
35delG carriers. Four SNPs were discovered,
two in the 3'UTR (SNP 1 and 2) and two in the
URR (SNP 3 and 4). The relative positions of
the SNPs with regard to the GJB2 gene are
depicted in fig 1, where the SNPs are placed on
the complete nucleotide sequence of clone
RP11-264J4 (Genbank accession number
AL138688). Several SNPs more distant from
the GJB2 gene were chosen from the SNP
Consortium LTD (http://snp.cshl.org/) and
analysed in random subjects. Two informative
SNPs, SNP 5 (TSC1102325) and SNP 6
(TSC0127952), were selected for further
analysis and positioned on the nucleotide
sequence of clone RP11-264J4 (fig 1).
SNP ANALYSIS
SNP analysis was performed using the ABI
Prism SNaPshot ddNTP Primer Extension Kit
(ABI) according to the manufacturer’s guide-
lines with minor modifications. PCR was
performed using standard conditions and the
primers and annealing temperatures listed in
table 2. PCR products were treated with 0.164
U/µl shrimp alkaline phosphatase (Promega)
and 0.164 U/µl exonuclease I (New England
Biolabs) for one hour at 37°C, followed by the
deactivation of the enzymes for 15 minutes at
72°C. SNaPshot thermal cycling was per-
formed with the respective SNaPshot primer
(table 2), the matching PCR product, and the
SNaPshot Ready Reaction Premix for 25
cycles of 10 seconds at 96°C denaturation, five
seconds at 50°C annealing, and 30 seconds at
60°C extension. SNaPshot products were
dephosphorylated by incubation at 37°C (one
hour) with 0.15 U/µl calf intestine alkaline
phosphatase (Gibco BRL Life Technologies).
The enzyme was deactivated as described
above and SNaPshot products were analysed
on an ABI3100 automated DNA sequencer
(ABI).
STATISTICAL ANALYSIS
DiVerences between groups were tested with ÷2
statistics, if at least 80% of the expected
frequencies exceeded 5 and all the expected
frequencies exceeded 1. If the expected values
did not meet the criteria mentioned above, the
numbers of the two least frequent alleles were
added and Yates’s correction for continuity for
two by two tables was used. If the expected
values of the two by two table still did not meet
the criteria mentioned above, Fisher’s exact
test was used. Both the ÷2 test and Fisher’s
exact test were calculated using the SigmaStat
2.0 software (Jandel Corporation). All p values
were taken to be significant at <0.05.
Results
In order to determine whether the high
frequency of the 35delG allele variant of GJB2
is the result of a mutational hot spot or a
founder eVect, SNPs adjacent to (SNPs 1 to 4,
fig 1) and more distant from (SNP 5 and 6, fig
1) GJB2 were analysed. Table 3 summarises
the genotypes observed in this study. SNP 1 is
very informative and results, even with small
sample numbers, in significantly diVerent
genotypes for controls and patients. SNPs 2
and 3 are less informative, as the allele that is
linked to 35delG (G for SNP 2 as well as for
SNP 3) is also the most frequent allele in the
Table 1 Carrier frequency of the 35delG mutation in various populations
Population
Subjects
tested
Carriers
35delG
Carrier
frequency
(%) Reference
Europe
Norway 190 1 0.5 22
Denmark 95 2 2.1 22
Estonia 113 5 4.4 22
Germany 200 4 2.0 22
UK 119 0 0.0 22
Holland 89 2 2.2 22
Belgium 190 1 0.5 22
Belgium 360 9 2.5 23
France (Brittany) 96 1 1.0 22
France 200 1 0.5 22
France 68 0 0.0 9
France 512 14 2.7 24
Bulgaria 157 1 0.6 22
Czech Republic 195 4 2.1 22
Slovenia 182 1 0.5 22
Italy (Sardinia) 116 4 3.4 22
Italy 255 8 3.1 22
Italy 150 6 4.0 12
Spain 200 5 2.5 22
Spain 130 3 2.3 22
Portugal 179 4 2.2 22
Malta 144 4 2.8 22
Greece 400 12 3.0 22
Greece 395 14 3.5 25
Turkey 150 4 2.7 22
North America
White Americans 173 1 0.6 17
White Americans 100 1 1.0 26
White Americans 96 2 2.0 11
White Americans 560 14 2.5 27
African Americans 173 0 0.0 17
African Americans 190 0 0.0 22
Asian Americans (Indian, Japanese, Koreans) 53 0 0.0 17
Ashkenazi Jewish Americans 551 4 0.7 17
Other populations
Egyptians 95 0 0.0 22
Arabs 58 1 1.7 22
Koreans 100 1 1 15
Figure 1 (A) Positions of the SNPs relative to the GJB2 gene. The GJB2 open reading
frame (ORF) is represented by the black box. The 3'UTR and the URR are represented by
shaded boxes. The borders of the ORF,UTR, and URR, the positions of the six SNPs, and
the 35delG mutation are indicated with their respective nucleotide numbers derived from the
genomic sequence of clone RP11-264J4 (Genbank accession number AL138688). (B) The
distance from each SNP to the 35delG mutation in the GJB2 gene (given in bp).
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general population. However, when using
larger sample numbers even these less informa-
tive SNPs show significant diVerences between
controls and patients. SNP 4 is informative,
giving significant diVerences even when using
smaller sample numbers. SNP 6, which is
approximately 63 kb away from the GJB2 gene,
only shows significant diVerences between
patients and controls in the total test popula-
tion (fig 1, table 1). For SNP 5, which is the
most remote SNP we investigated (approxi-
mately 76 kb away from GJB2, fig 1), no
significant association with the 35delG muta-
tion could be found. We conclude that the high
frequency of the 35delG mutation in GJB2 is
the result of a founder eVect.
The 35delG mutation must have arisen
many centuries ago as haplotype sharing is
observed only in a small region. On the basis of
the recombination frequency of a more distant
SNP, we can estimate the age of the 35delG
mutation. From one generation to the next, the
probability of having a recombination between
a gene and a nearby marker is equal to the
recombination fraction è. In one generation, a
fraction è of all sibs will have a recombination
and a fraction 1-è will not. After N generations,
the fraction of descendants that has no recom-
bination equals (1-è)N. When examining SNP 6
in the total test population and assuming A was
the allele associated with the 35delG mutation
in the founder, 161 out of 224 chromosomes
showed no recombination in a region of
approximately 63 kb (assumed to correspond
to è=0.00063). Consequently, the 35delG
mutation is estimated to be about 500 genera-
tions, or approximately 10 000 years old. As we
do not know the true recombination frequency
of this region, it should be emphasised that this
calculation represents no more than a rough
estimation, and that the range of error for this
calculation is undoubtedly large.
Discussion
In this study, we show that the high frequency
of the 35delG mutation is the result of a
founder eVect rather than a mutational hot
spot, although the latter hypothesis has been
favoured by most authors.9 11 17 20 21 It has been
argued that the deletion of one G from a stretch
of six could have arisen frequently through
polymerase slippage or the presence of a chi
consensus motif in the immediate vicinity.9 11 A
strong argument for a mutational hot spot is
certainly the presence of this mutation in
several geographically and ethnically distinct
populations.21 However, its absence or low
prevalence in other ethnic groups, such as
Asians,14 15 argues against this hypothesis.
Morell et al17 have shown that several diVer-
ent haplotypes surround the 35delG muta-
tion,17 another strong argument in favour of a
mutational hot spot. Their study considered an
interval of 2 cM, while we have focused on a
region of less than 70 kb or more than 95%
smaller. As we have shown, the 35delG
mutation is ancient and therefore haplotype
sharing will be observed only in a very small
chromosomal interval.
The age of the mutation further explains its
widespread occurrence across Europe, the
Mediterranean region, and the United States.
Possibly, the mutation originated somewhere in
the Middle East and was spread throughout
Europe along the two Neolithic population
movement routes. The first route followed the
coast of the Mediterranean sea to Italy and
Spain, while the other followed the Danube
and Rhine valleys to northern Europe. The
35delG mutation would have been brought to
the United States by emigration from Europe.
Table 2 PCR and SNaPshot primers
SNP Primer Primer sequence
Annealing
temperature
(°C)
Length of
PCR product
(bp)
SNP 1 F aggcactggtaactttgtcc 59 589
R gtgtctggaatttgcatcctgc
SNaPshot agctgtcaaggctcagtcgc
SNP 2 F caatgctattcttgacaacagg 59 901
R ccacgttaaaggtgaacattgg
SNaPshot acctctttaaatcagcgttctttcc
SNP 3 F ctgtgtgatgttggctagtcg 56 676
R gacaccacagtgagttttcc
SNaPshot ctgccctagaggagtcctgagcctacttgg
SNP 4 F gcttaggatagtactgctgc 56 502
R cacggtgccattccatcagg
SNaPshot ctcattgacgtgcagagactgaccagatagagaag
SNP 5 F ctgagtaccaatctcaccac 56 230
R tgcacagggataataaccgc
SNaPshot gggcccttaaacatgaggc
SNP 6 F taacaaggcctccaagtgac 55 381
R gcttgccatcaagaaaggag
SNaPshot tcagcgtcatctctttggactgca
Table 3 Results of the SNP analysis
SNP Genotype
Belgian British American Total
Patient Control p Patient Control p Patient Control p Patient Control p
SNP 1 CC 0 47 <0.001 0 18 <0.001 0 31 <0.001 0 96 <0.001
CT 0 13 2 12 2 18 4 43
TT 33 1 27 0 45 1 105 2
SNP 2 GG 31 20 0.014 27 24 0.025 47 43 0.013 105 87 <0.001
GA 0 5 0 6 0 7 0 18
AA 0 0 0 0 0 0 0 0
SNP 3 GG 33 29 0.053 29 25 0.052 49 41 0.003 111 95 <0.001
GA 0 5 0 5 0 9 0 19
AA 0 0 0 0 0 0 0 0
SNP 4 TT 31 22 0.008 28 20 <0.001 48 35 <0.001 107 77 <0.001
TG 0 6 0 10 0 14 0 30
GG 0 0 0 0 0 0 0 0
SNP 5 GG 26 21 0.611 22 20 0.472 35 31 0.613 83 72 0.358
GA 6 8 5 10 13 13 24 31
AA 2 2 1 0 1 4 4 6
SNP 6 GG 6 5 0.072 6 3 0.431 3 6 0.224 15 14 0.019
GA 10 17 6 13 17 22 33 52
AA 19 9 17 13 28 22 64 44
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The low carrier frequency seen in other popu-
lations, for example, in the Korean and Arab
population, could also have originated from the
same founder. On the other hand, however, it
cannot be excluded that the 35delG mutation
has arisen on more then one occasion.
The reason for the high frequency of 35delG
remains to be elucidated. By comparison, the
ÄF508 cystic fibrosis mutation is by far the best
known and studied ancient mutation. Its
frequency varies in diVerent populations and
estimates of age of origin of the mutation
range, from 2940 to 52 000 years, depending
on the methods used.28 29 It has been postulated
that ÄF508 carriers have an increased resist-
ance to chloride secreting diarrhoea resulting
in selective advantage for heterozygous carri-
ers.30 At present, it is not known whether the
carrier status for a mutation in GJB2 is associ-
ated with increased reproductive fitness.
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